Press Releases

Date Title and Summary Additional Formats
Toggle Summary A Tribute to Alex Barkas View HTML
Toggle Summary Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment CRANBURY, N.J. , and CHARLOTTE, N.C. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics
View HTML
Toggle Summary Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment Conference Call at 8:30 a.m. ET Today CRANBURY, N.J. , Aug.
View HTML
Toggle Summary Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
John F. Crowley provides perspectives and recommendations to Committee on treating rare and neglected pediatric diseases and promoting the development of new treatments-
View HTML
Toggle Summary Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and PHILADELPHIA , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it is
View HTML
Toggle Summary Amicus Therapeutics (FOLD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Company to Celebrate Initial Public Offering On NASDAQ
View HTML
Toggle Summary Amicus Therapeutics Achieves Target Enrollment in Second Phase 3 Fabry Monotherapy Study
56 Patients Now Randomized to Switch from Enzyme Replacement Therapy (ERT) to Migalastat HCl or to Remain on ERT Final Enrollment Expected Ahead of Year-End Target CRANBURY, N.J. , Oct. 22, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of
View HTML
Toggle Summary Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
License with Nationwide Children’s Hospital ( NCH ) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases              
View HTML
Toggle Summary Amicus Therapeutics Added to NASDAQ Biotechnology Index
CRANBURY, N.J. , May 21, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ Biotechnology Index (Nasdaq:NBI) (Nasdaq:XNBI) after the
View HTML
Toggle Summary Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI)
CRANBURY, N.J. , Dec. 22, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ Biotechnology Index (Nasdaq:NBI) (Nasdaq:XNBI), effective
View HTML